Phase II Open Label Nonrandomized Single Arm Trial of the Anti PD 1 Therapy Pembrolizumab in Combination with First Line Platinum Based Chemotherapy Followed by 12 Months Maintenance Pembrolizumab Monotherapy for Patients with Sub Optimally Cytoreduced Stage III/IV Epithelial Ovarian Cancer

Protocol No
IIT-UYAR-MERCK-MISP52444
Principal Investigator
Denise Uyar
Phase
II
Summary
This study is being done to determine if using that anti-PD therapy combined with standard chemotherapy will improve the PFS in patients with suboptimally cytoreduced epithelial ovarian/ primary peritoneal/ fallopian tube cancer and have a tolerable safety profile.
Description
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Participating Institutions
Cleveland Clinic
Hillcrest Hospital
Froedtert Hospital
Fairview Hospital, Moll Pavilion Cancer Center
Status
OPEN TO ACCRUAL
Share This: